- Synonyms
-
- Source
- Escherichia coli.
- Molecular Weight
- Approximately 20.0 kDa, a single non-glycosylated polypeptide chain containing 166 amino acids.
- AA Sequence
- MSYNLLGFLQ RSSNFQCQKL LWQLNGRLEY CLKDRMNFDI PEEIKQLQQF QKEDAALTIY EMLQNIFAIF RQDSSSTGWN ETIVENLLAN VYHQINHLKT VLEEKLEKED FTRGKLMSSL HLKRYYGRIL HYLKAKEYSH CAWTIVRVEI LRNFYFINRL TGYLRN
- Purity
- > 97 % by SDS-PAGE and HPLC analyses.
- Biological Activity
- Fully biologically active when compared to standard. The specific activity determined by an anti-viral assay is no less than 3.0 × 107 IU/mg.
- Physical Appearance
- Sterile Filtered White lyophilized (freeze-dried) powder.
- Formulation
- Lyophilized from a 0.2 µm filtered concentrated solution in PBS, pH 7.4, containing 2 % HSA and 3 % mannitol.
- Endotoxin
- Less than 1 EU/µg of rHuIFN-β1b as determined by LAL method.
- Reconstitution
- We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
- Stability & Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.
- Usage
- This material is offered by Shanghai PrimeGene Bio-Tech for research, laboratory or further evaluation purposes. NOT FOR HUMAN USE.
- Reference
- 1. Yoshino A, Tashiro S, Ogino A, et al. 2011. Int J Oncol, 39: 529-42.
2. Farrell RA, Marta M, Gaeguta AJ, et al. 2012. Rheumatology (Oxford), 51: 590-9.
3. Breckpot K, Corthals J, Bonehill A, et al. 2005. J Leukoc Biol, 78: 898-908.
4. Oger J, Francis G, Chang P. 2005. J Neurol Sci, 237: 45-52.
5. Giorelli M, Livrea P, Trojano M. 2005. J Interferon Cytokine Res, 25: 395-406.
- Background
- IFN-βs are proteins produced by many cell types including lymphocytes (NK cells, B-cells and T-cells), macrophages, fibroblasts, endothelial cells, osteoblasts and others. They have antiviral activity that it is mainly involved in innate immune response. The IFN-β family has 2 subtypes,which are IFN-β1 (IFNB1) and IFN-β3 (IFNB3) (a gene designated IFN-β2 is actually IL-6). IFN-β1 is used as a treatment for multiple sclerosis as it reduces the relapse rate.